KR920006335A - 안지오텐신 ⅱ수용체 길항제 - Google Patents

안지오텐신 ⅱ수용체 길항제 Download PDF

Info

Publication number
KR920006335A
KR920006335A KR1019910015665A KR910015665A KR920006335A KR 920006335 A KR920006335 A KR 920006335A KR 1019910015665 A KR1019910015665 A KR 1019910015665A KR 910015665 A KR910015665 A KR 910015665A KR 920006335 A KR920006335 A KR 920006335A
Authority
KR
South Korea
Prior art keywords
lower alkyl
hydrogen
coor
substituted
halo
Prior art date
Application number
KR1019910015665A
Other languages
English (en)
Inventor
윈 마틴
드 비스워나트
엠. 지도우스키 토마스
제이. 커크만 다니엘
에프. 드버나디스 존
에이. 로젠버그 사울
가즈미 시오사키
제트.바샤 파티마
에스. 타스커 앤드류
더블유. 폰 겔던 토마스
에이. 케스터 제프리
에이치. 홀레만 윌리암
Original Assignee
챨스 엠. 브룩
애보트 래보러토리즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 챨스 엠. 브룩, 애보트 래보러토리즈 filed Critical 챨스 엠. 브룩
Publication of KR920006335A publication Critical patent/KR920006335A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

내용 없음

Description

안지오텐신 ∥수용체 길항제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 일반식(Ⅳ)의 화합물, 약제학적으로 허용되는 이의 염 또는 이의 예비약제.
    상기식에서, n은 0 또는 1이고, A는 공유 결합, -O- 및 -C(O)- 중에서 선택되며, B는 -N(R4)-(여기서, R4는 수소, 저급 알킬, 저급 알콕시-치환된 저급 알킬, 저급 알케닐, 저급 알키닐, 사이클로알킬 또는 사이클로 알킬알킬이다).-O- 및 -S-중에서 선택되며, R1은 테트라졸릴, -COOR5-또는 -CH2COOR5(여기서, R5는 수소 또는 카복시보호 그룹이다);및 -NHS(O)2R6또는 -CH2NHS(O)2R6(여기서, R6은 저급 알킬 및 할로-치환된 저급 알킬 중에서 선택된다)중에서 선택되며, R3은 수소, 저급 알킬, 할로-치환된 저급 알킬, -CN, -NO2, -NH2, -CHO, 테트라졸릴, -HNS(O)2R9, -NHC(O)R9-NHC(O)R9또 -CH2NHS(O)2R9(여기서 R9는 저급 알킬 및 할로-치환된 저급 알킬 중에서 선택된다)-COOR10또는 -CH2COOR10(여기서, R10은 수소 또는 카복시-보호그룹이다),-C(O)NR11R12,-CH2C(O)NR11R12, -KNHC(O)NR11R12, 또는 -CH2NHC(O)NR11R12(여기서, R11및 R12독립적으로 수소, 저급 알킬, 하이드록시, 저급 알콕시, 하이드록시-치환된 저급알킬, 저급 알콕시-치환된 저급 알킬 및 저급알콕시-치환된 저급알콕시 중에서 선택되거나, R11및 R12는 이들이 결합된 질소원자와 함께 5-내지7-원 지방족 헤테로사이클을 형성한다). -CH2OR13[여기서, R13은 수소, 저급알킬 및 -C(O)R14(여기서, R14는 수소, 저급 알킬 또는 아릴이다)중에서 선택된다]. -CH2NR15R15*[여기서, R15는 수소, 저급 알킬, -C(O)R16, -C(O)R16R16*및 -S(O)2R17(여기서 R16은 수소, 저급알킬 및 아릴 중에서 선택되고, R17은 저급 알킬 및 할로-치환된 저급 알킬 중에서 선택되며, R15*및 R16*은 독립적으로 수소, 저급알킬, 하이드록시 및 저급 알콕시중에서 선택된다)중에서 선택된다], -SO3H 또는 -CH2SO3H 및 -SO2NR11R12또는 -CH2SO2NR11R12(여기서, R11및 R12는 상기 정의한 바와 같다)중에서 선택된다.
  2. 제1항에 있어서, R1이 테트라졸리이고, n이 1이고, A는 결합이며, B는 NR4이고 R3은 -COOR10또는 -C(O)NR11R12인 화합물.
  3. 일반식(IA)의 화합물, 약제학적으로 허용되는 이의 염 또는 이의 예비약제.
    상기식에서, n은 0 또는 1이고, A는 공유 결합, -O- 및 -C(O)- 중에서 선택되며, B는 -N(R4)-(여기서, R4는 수소, 저급 알킬, 저급 알콕시-치환된 저급 알킬, 저급 알케닐, 저급 알키닐, 사이클로알킬 또는 사이클로 알킬알킬이다).-O- 및 -S-중에서 선택되며, R1은 테트라졸릴, -COOR5-또는 -CH2COOR5(여기서, R5는 수소 또는 카복시보호 그룹이다);및 -NHS(O)2R6또는 -CH2NHS(O)2R6(여기서, R6은 저급 알킬 및 할로-치환된 저급 알킬 중에서 선택된다)중에서 선택되며, R3은 수소, 저급 알킬, 할로-치환된 저급 알킬, -CN, -NO2, -NH2, -CHO, 테트라졸릴, -HNS(O)2R9, -NHC(O)R9-NHC(O)R9또 -CH2NHS(O)2R9(여기서 R9는 저급 알킬 및 할로-치환된 저급 알킬 중에서 선택된다)-COOR10또는 -CH2COOR10(여기서, R10은 수소 또는 카복시-보호그룹이다),-C(O)NR11R12,-CH2C(O)NR11R12, -KNHC(O)NR11R12, 또는 -CH2NHC(O)NR11R12(여기서, R11및 R12독립적으로 수소, 저급 알킬, 하이드록시, 저급 알콕시, 하이드록시-치환된 저급알킬, 저급 알콕시-치환된 저급 알킬 및 저급알콕시-치환된 저급알콕시 중에서 선택되거나, R11및 R12는 이들이 결합된 질소원자와 함께 5-내지7-원 지방족 헤테로사이클을 형성한다). -CH2OR13[여기서, R13은 수소, 저급알킬 및 -C(O)R14(여기서, R14는 수소, 저급 알킬 또는 아릴이다)중에서 선택된다]. -CH2NR15R15*[여기서, R15는 수소, 저급 알킬, -C(O)R16, -C(O)R16R16*및 -S(O)2R17(여기서 R16은 수소, 저급알킬 및 아릴 중에서 선택되고, R17은 저급 알킬 및 할로-치환된 저급 알킬 중에서 선택되며, R15*및 R16*은 독립적으로 수소, 저급알킬, 하이드록시 및 저급 알콕시중에서 선택된다)중에서 선택된다], -SO3H 또는 -CH2SO3H 및 -SO2NR11R12또는 -CH2SO2NR11R12(여기서, R11및 R12는 상기 정의한 바와 같다)중에서 선택된다.
  4. 제3항에 있어서, R1이 테트라졸릴이고, n이 1이고, A는 결합이며, B는 NR4이고 R3은 -COOR10또는 -C(O)NR11R12인 화합물.
  5. 4-{N-부틸-N-(2'-1H-테트라졸-5-일)비페닐-4-일)메틸)아미노}피리미딘-5-카복실산, 피발로일옥시메틸 4-{N-부틸-N-(2'-1H-테트라졸-5-일)비페닐-4-일)메틸)아미노}피리미딘-5-카복실레이트,2-{N-프로필-N-((2'-1H-테트라졸-5-일)비페닐-4-일)메틸)아미노}피리미딘-3-카복실산, 1-(에틸옥시카보닐옥시)에틸 4-{N-부틸-N-(2'-1H-테트라졸-5-일)비페닐-4-일)메틸)아미노}피리미딘-5-카복실레이트,2-{N-부틸-N-((2'-(1H-테트라졸-5-일)비페닐-4-일)메틸)아미노}피리딘-3-카복실산,2-{N-알릴-N-((2'-(1H-테트라졸-5-일)비페닐-4-일)메틸)아미노}피리미딘-3-카복실산으로 이루어진 그룹으로부터 선택된 화합물. 또는 약제학적으로 허용되는 이의 염 또는 이의 에스테르.
  6. 일반식(I)의 화합물, 약제학적으로 허용되는 이의 염 또는 이의 예비약제.
    상기식에서, n은 0 또는 1이고, A는 공유 결합, -O- 및 -C(O)- 중에서 선택되며, B는 -N(R4)-(여기서, R4는 수소, 저급 알킬, 저급 알콕시-치환된 저급 알킬, 저급 알케닐, 저급 알키닐, 사이클로알킬 또는 사이클로 알킬알킬이다).-O- 및 -S-중에서 선택되며, R1은 테트라졸릴, -COOR5-또는 -CH2COOR5(여기서, R5는 수소 또는 카복시보호 그룹이다);및 -NHS(O)2R6또는 -CH2NHS(O)2R6(여기서, R6은 저급 알킬 및 할로-치환된 저급 알킬 중에서 선택된다)중에서 선택되며, R3은 수소, 저급 알킬, 할로-치환된 저급 알킬, -CN, -NO2, -NH2, -CHO, 테트라졸릴, -HNS(O)2R9, -NHC(O)R9-NHC(O)R9또 -CH2NHS(O)2R9(여기서 R9는 저급 알킬 및 할로-치환된 저급 알킬 중에서 선택된다)-COOR10또는 -CH2COOR10(여기서, R10은 수소 또는 카복시-보호그룹이다),-C(O)NR11R12,-CH2C(O)NR11R12, -KNHC(O)NR11R12, 또는 -CH2NHC(O)NR11R12(여기서, R11및 R12독립적으로 수소, 저급 알킬, 하이드록시, 저급 알콕시, 하이드록시-치환된 저급알킬, 저급 알콕시-치환된 저급 알킬 및 저급알콕시-치환된 저급알콕시 중에서 선택되거나, R11및 R12는 이들이 결합된 질소원자와 함께 5-내지7-원 지방족 헤테로사이클을 형성한다). -CH2OR13[여기서, R13은 수소, 저급알킬 및 -C(O)R14(여기서, R14는 수소, 저급 알킬 또는 아릴이다)중에서 선택된다]. -CH2NR15R15*[여기서, R15는 수소, 저급 알킬, -C(O)R16, -C(O)R16R16*및 -S(O)2R17(여기서 R16은 수소, 저급알킬 및 아릴 중에서 선택되고, R17은 저급 알킬 및 할로-치환된 저급 알킬 중에서 선택되며, R15*및 R16*은 독립적으로 수소, 저급알킬, 하이드록시 및 저급 알콕시중에서 선택된다)중에서 선택된다], -SO3H 또는 -CH2SO3H 및 -SO2NR11R12또는 -CH2SO2NR11R12(여기서, R11및 R12는 상기 정의한 바와 같다)중에서 선택된다.
  7. 안지오텐신 Ⅱ와 안지오텐신 Ⅱ 수용체의 상호작용을 차단하기 위한, 약제학적으로 허용되는 담체 및 제6항의 화합물 치료적 유효량을 함유하는 약제학적 조성물.
  8. 고혈압, 부종, 울형성 심장마비를 치료하거나 아테롬성동맥경화증을 예방하기 위한, 약제학적으로 허용되는 담체 및 제6항의 화합물 치료적 유효량을 함유하는 약제학적 조성물.
  9. 제6의 화합물 치료적 유효량을 치료를 요하는 인체 또는 기타 포유류에게 투여함을 특징으로 하여, 안지오텐신 Ⅱ수용체의 상호작용을 차단하는 방법.
  10. 제6항의 화합물 치료적 유효량을 치료를 요하는 인체 또는 기타 포유류에게 투여함을 특징으로 하여, 고혈압, 부종, 울형성 심장마비를 치료하거나 아테롬성동맥경화증을 예방하는 방법.
  11. 일반식(여기서, A,B,R1및 n은 제6항에서 정의한 바와 같다)의 화합물을 일반식(여기서, X,Y,Z,W 및 W는 제6항에서 정의한 바와 같다)의 화합물과 반응시킴을 특징으로 하여, 제6항의 화합물을 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910015665A 1990-09-10 1991-09-09 안지오텐신 ⅱ수용체 길항제 KR920006335A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58040090A 1990-09-10 1990-09-10
US07/580,400 1990-09-10
US74424191A 1991-08-15 1991-08-15
US07/744,241 1991-08-15

Publications (1)

Publication Number Publication Date
KR920006335A true KR920006335A (ko) 1992-04-27

Family

ID=27078031

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910015665A KR920006335A (ko) 1990-09-10 1991-09-09 안지오텐신 ⅱ수용체 길항제

Country Status (8)

Country Link
EP (1) EP0475206A3 (ko)
JP (2) JPH04261156A (ko)
KR (1) KR920006335A (ko)
AU (1) AU647174B2 (ko)
CA (1) CA2050723A1 (ko)
IE (1) IE912956A1 (ko)
IL (1) IL99246A0 (ko)
PT (1) PT98908A (ko)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198439A (en) * 1990-04-19 1993-03-30 Imperial Chemical Industries Plc Angiotension II antagonizing pyridine derivatives
CA2051705A1 (en) * 1990-06-19 1991-12-20 Kiyoaki Katano Pyridine derivatives having angiotensin ii antagonism
US5284954A (en) * 1990-09-10 1994-02-08 Abbott Laboratories Process for the preparation of tetrazoles
IE920175A1 (en) * 1991-02-11 1992-08-12 Zeneca Ltd Nitrogen heterocycles
GB9102803D0 (en) * 1991-02-11 1991-03-27 Ici Plc Pyridine compounds
GB9102804D0 (en) * 1991-02-11 1991-03-27 Ici Plc Heterocyclic derivatives
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
IL101860A0 (en) * 1991-05-31 1992-12-30 Ici Plc Heterocyclic derivatives
GB9113628D0 (en) * 1991-06-25 1991-08-14 Ici Plc Heterocyclic derivatives
GB9113626D0 (en) * 1991-06-25 1991-08-14 Ici Plc Heterocyclic compounds
GB9121727D0 (en) * 1991-10-14 1991-11-27 Ici Plc Heterocyclic compounds
US5336677A (en) * 1991-10-24 1994-08-09 American Home Products Corporation Substituted aminopyrimidines as antihypertensives
GB9125842D0 (en) * 1991-12-04 1992-02-05 Ici Plc Heterocyclic derivatives
US5364869A (en) * 1992-03-09 1994-11-15 Abbott Laboratories Heterocycle-substituted benzyaminopyridine angiotensin II receptor antagonists
DE4215587A1 (de) * 1992-05-12 1993-11-18 Bayer Ag Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone
GB9211292D0 (en) * 1992-05-28 1992-07-15 Ici Plc Heteroecyclic compounds
GB9218449D0 (en) 1992-08-29 1992-10-14 Boots Co Plc Therapeutic agents
ATE167861T1 (de) * 1992-09-14 1998-07-15 Takeda Chemical Industries Ltd 1,2,4-oxadiazolyl oder 1,2,4-thiadiazolyl- derivate als angiotensin ii antagonisten
JPH06239859A (ja) * 1992-09-14 1994-08-30 Takeda Chem Ind Ltd アンギオテンシンｉｉ拮抗作用を有する環状化合物およびその用途
TW259786B (ko) * 1992-12-17 1995-10-11 Sankyo Co
US5721264A (en) * 1993-04-07 1998-02-24 Nissan Chemical Industries, Ltd. Pyrazole derivatives
WO1995026188A1 (en) * 1994-03-29 1995-10-05 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
US5585381A (en) 1994-06-01 1996-12-17 Kureha Chemical Industry Co., Ltd. Pyrimidine derivatives and pharmaceutical composition
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
GB9417532D0 (en) * 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
GB9420557D0 (en) * 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
TW434240B (en) * 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
TW502026B (en) * 1995-06-20 2002-09-11 Zeneca Ltd Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
EP0752421B1 (en) * 1995-07-07 2005-10-12 AstraZeneca AB Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
US5811428A (en) * 1995-12-18 1998-09-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
AU7213296A (en) * 1995-10-06 1997-04-30 Ciba-Geigy Ag At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
AU1791497A (en) 1996-02-29 1997-09-16 Novartis Ag At1 receptor antagonist for the stimulation of apoptosis
JPH10203981A (ja) * 1997-01-21 1998-08-04 Kureha Chem Ind Co Ltd 心疾患改善剤
EP1054004B1 (en) 1997-12-15 2008-07-16 Astellas Pharma Inc. Novel pyrimidine-5-carboxamide derivatives
BR9908474A (pt) * 1998-03-04 2000-12-05 Takeda Chemical Industries Ltd Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica
AU767456B2 (en) * 1998-07-06 2003-11-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
DE69903053T2 (de) * 1998-10-02 2003-05-22 Neurosearch As Ballerup Diaminocyclobuten-3,4-dionderivate, deren herstellung und deren verwendung
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2000038676A1 (en) 1998-12-23 2000-07-06 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009051112A1 (ja) * 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited アミド化合物およびその用途
EP3239170B1 (en) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
EA202090205A1 (ru) 2017-07-07 2020-06-02 Бёрингер Ингельхайм Ветмедика Гмбх Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
EP0407342A3 (en) * 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
EP0424317A3 (en) * 1989-10-19 1991-09-25 Ciba-Geigy Ag Pyrimidines
EP0453210A3 (en) * 1990-04-19 1993-01-13 Imperial Chemical Industries Plc Pyridine derivatives
CA2051705A1 (en) * 1990-06-19 1991-12-20 Kiyoaki Katano Pyridine derivatives having angiotensin ii antagonism

Also Published As

Publication number Publication date
EP0475206A3 (en) 1992-08-05
JPH04261156A (ja) 1992-09-17
JPH0753551A (ja) 1995-02-28
AU8374491A (en) 1992-03-12
EP0475206A2 (en) 1992-03-18
CA2050723A1 (en) 1992-03-11
PT98908A (pt) 1992-07-31
IL99246A0 (en) 1992-07-15
AU647174B2 (en) 1994-03-17
IE912956A1 (en) 1992-03-11

Similar Documents

Publication Publication Date Title
KR920006335A (ko) 안지오텐신 ⅱ수용체 길항제
KR100559192B1 (ko) 혈관신생 촉진제 및 혈관신생 작용증강제
KR920006323A (ko) 아자사이클릭 화합물
ATE300941T1 (de) Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
KR960704884A (ko) 항종양제 또는 항바이러스제로서의 디스타마이신 A 동족체 (Distamycin A analogues as antitumour or antiviral agents)
KR890001537A (ko) 5ht-3 길항제의 용도
ATE346628T1 (de) Injektionssystem für die applikation halbfester, depotförmiger pharmazeutischer zusammensetzungen aus gelierbaren peptidsalzen
RU97106829A (ru) Производные имидазола
CA2328990A1 (en) N,n-disubstituted amides that inhibit the binding of integrins to their receptors
JP2001526269A5 (ko)
WO1998002151A3 (en) Chemokine receptor antagonists and methods of use therefor
JP2001526218A5 (ko)
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
IL137266A0 (en) Heterocyclic chemokine receptor antagonists and pharmaceutical compositions containing the same
KR940005623A (ko) 이미다조피리딘
KR930701415A (ko) 약학적으로 활성인 벤조퀴나졸린 화합물
CA2232191A1 (en) Inhibition of tumor necrosis factor alpha
KR920008046A (ko) 티에노이미다졸 유도체, 그의 제조방법 및 용도
KR890009864A (ko) 신규 화합물들
CA2099447A1 (en) Angiotensin ii receptor antagonists for the treatment and prophylaxis of coronary heart disease
KR870007937A (ko) 2β-치환된 티오 메틸페니실린 유도체 및 그의 제조방법 및 용도
KR930019631A (ko) 2-옥소퀴놀린 유도체
KR970706272A (ko) 치료에 유용한 바이시클릭 아미딘 유도체(Bicyclic Amidine Derivatives Useful in Therapy)
KR900014362A (ko) 인돌 유도체
RU98106104A (ru) Производные пиримидина

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid